Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from GeoVax Labs ( (GOVX) ).
On March 31, 2026, GeoVax Labs entered into a warrant inducement agreement with existing healthcare-focused institutional investors, who agreed to immediately exercise warrants for up to 634,658 common shares at a reduced price of $1.36, generating gross proceeds of about $863,000 for working capital and general corporate purposes. In return, investors will receive new unregistered warrants to purchase up to 1,269,316 additional shares at the same exercise price, exercisable for five years following shareholder approval, a move that bolsters GeoVax’s near-term liquidity while increasing potential future share dilution and further aligning financing with the company’s biotech development pipeline.
The most recent analyst rating on (GOVX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, large losses, and sustained cash burn) and bearish technicals (below key moving averages with negative momentum). The main offset is the earnings-call catalyst around an expedited EMA development pathway and partnership interest, while valuation signals are limited due to negative earnings and no stated dividend.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies targeting high-consequence infectious diseases and solid tumor cancers. Its lead program, GEO-MVA, is an MVA-based mpox and smallpox vaccine moving toward a pivotal Phase 3 trial in 2026, alongside oncology candidate Gedeptin and next-generation COVID-19 vaccine GEO-CM04S1.
Average Trading Volume: 140,665
Technical Sentiment Signal: Sell
Current Market Cap: $3.02M
For a thorough assessment of GOVX stock, go to TipRanks’ Stock Analysis page.